U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244926) titled 'Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer' on Nov. 17.
Brief Summary: In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus platinum-based chemotherapy.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Intervention:
DRUG: Sacituzumab tirumotecan plus bevacizumab
The eligible patients will receive intravenous sac-TMT 4mg/kg every 2 weeks plus intravenous bevacizumab 10mg/kg eve...